{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:07:34Z","timestamp":1787933254639,"version":"build-2784847793"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"IntraBio Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Niemann-Pick disease type C (NPC) is a rare autosomal recessive neurodegenerative lysosomal disease characterized by multiple symptoms such as progressive cerebellar ataxia and cognitive decline. The modified amino acid N-acetyl-leucine has been associated with positive symptomatic and neuroprotective, disease-modifying effects in various studies, including animal models of NPC, observational clinical case studies, and a multinational, rater-blinded phase IIb clinical trial. Here, we describe the development of a study protocol (Sponsor Code \u201cIB1001-301\u201d) for the chronic treatment of symptoms in adult and pediatric patients with NPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multinational double-blind randomized placebo-controlled crossover phase III study will enroll patients with a genetically confirmed diagnosis of NPC patients aged 4\u00a0years and older across 16 trial sites. Patients are assessed during a baseline period and then randomized (1:1) to one of two treatment sequences: IB1001 followed by placebo or vice versa. Each sequence consists of a 12-week treatment period. The primary efficacy endpoint is based on the Scale for the Assessment and Rating of Ataxia, and secondary outcomes include cerebellar functional rating scales, clinical global impression, and quality of life assessments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Pre-clinical as well as observational and phase IIb clinical trials have previously demonstrated that IB1001 rapidly improved symptoms, functioning, and quality of life for pediatric and adult NPC patients and is safe and well tolerated. In this placebo-controlled cross-over trial, the risk\/benefit profile of IB1001 for NPC will be evaluated. It will also give information about the applicability of IB1001 as a therapeutic paradigm for other rare and common neurological disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registrations<\/jats:title>\n                    <jats:p>\n                      The trial (IB1001-301) has been registered at\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">www.clinicaltrials.gov<\/jats:ext-link>\n                      (NCT05163288) and\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrialsregister.eu\">www.clinicaltrialsregister.eu<\/jats:ext-link>\n                      (EudraCT: 2021\u2013005356-10).\u00a0Registered on\u00a020 December 2021.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-023-07399-6","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T02:02:31Z","timestamp":1685325751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["N-acetyl-L-leucine for Niemann-Pick type C: a multinational double-blind randomized placebo-controlled crossover study"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9506-4055","authenticated-orcid":false,"given":"T","family":"Fields","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"M. Bremova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Billington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GC","family":"Churchill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Fields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Galione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Mathieson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Martakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Factor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Strupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,29]]},"reference":[{"key":"7399_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13023-018-0785-7","volume":"13","author":"T Geberhiwot","year":"2018","unstructured":"Geberhiwot T, Moro A, Dardis A, et al. Consensus clinical management guidelines for Niemann-Pick disease type C. Orphanet J Rare Dis. 2018;13:50.","journal-title":"Orphanet J Rare Dis"},{"key":"7399_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1034\/j.1399-0004.2003.00147.x","volume":"64","author":"MT Vanier","year":"2003","unstructured":"Vanier MT, Millat G. Niemann-Pick disease type C. Clin Genet. 2003;64:269\u201381.","journal-title":"Clin Genet"},{"key":"7399_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1212\/CPJ.0000000000000399","volume":"7","author":"MC Patterson","year":"2017","unstructured":"Patterson MC, Clayton P, Gissen P, et al. Recommendations for the detection and diagnosis of Niemann-Pick disease type C: an update. Neurol Clin Pract. 2017;7:499\u2013511.","journal-title":"Neurol Clin Pract"},{"key":"7399_CR4","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1212\/WNL.0000000000002041","volume":"85","author":"T Bremova","year":"2015","unstructured":"Bremova T, Malinov\u00e1 V, Amraoui Y, et al. Acetyl-dl-leucine in Niemann-Pick type C: a case series. Neurology. 2015;85:1368\u201375.","journal-title":"Neurology"},{"key":"7399_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13023-018-0880-9","volume":"13","author":"M Cortina-Borja","year":"2018","unstructured":"Cortina-Borja M, Te Vruchte D, Mengel E, et al. Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials. Orphanet J Rare Dis. 2018;13:143.","journal-title":"Orphanet J Rare Dis"},{"key":"7399_CR6","doi-asserted-by":"publisher","unstructured":"Kaya E, Smith DA, Smith C, et al. Acetyl-leucine slows disease progression in lysosomal storage disorders. Brain Commun. 2020;fcaa148, https:\/\/doi.org\/10.1093\/braincomms\/fcaa148.","DOI":"10.1093\/braincomms\/fcaa148"},{"key":"7399_CR7","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s00415-021-10717-0","volume":"269","author":"T Bremova-Ertl","year":"2022","unstructured":"Bremova-Ertl T, Claassen J, Foltan T, et al. Efficacy and safety of N-acetyl-L-leucine in Niemann-Pick disease type C. J Neurol. 2022;269:1651\u201362.","journal-title":"J Neurol"},{"key":"7399_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13063-020-05009-3","volume":"22","author":"T Fields","year":"2021","unstructured":"Fields T, Patterson M, Bremova-Ertl T, et al. A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia. Trials. 2021;22:84.","journal-title":"Trials"},{"key":"7399_CR9","doi-asserted-by":"crossref","unstructured":"Martakis K, Claassen J, Gascon-Bayarri J, et al. N-acetyl-L-leucine improves symptoms and functioning in GM2 Gangliosidosis (Tay-Sachs & Sandhoff). medRxiv; 2021. p. 2021.09.24.21264020. Accessed at: https:\/\/www.medrxiv.org\/content\/10.1101\/2021.09.24.21264020v1. Accessed 3 Aug 2022.","DOI":"10.1101\/2021.09.24.21264020"},{"key":"7399_CR10","doi-asserted-by":"publisher","first-page":"15812","DOI":"10.1038\/s41598-021-95255-5","volume":"11","author":"GC Churchill","year":"2021","unstructured":"Churchill GC, Strupp M, Factor C, et al. Acetylation turns leucine into a drug by membrane transporter switching. Sci Rep. 2021;11:15812.","journal-title":"Sci Rep"},{"key":"7399_CR11","doi-asserted-by":"publisher","first-page":"e0120891","DOI":"10.1371\/journal.pone.0120891","volume":"10","author":"L G\u00fcnther","year":"2015","unstructured":"G\u00fcnther L, Beck R, Xiong G, et al. N-acetyl-L-leucine accelerates vestibular compensation after unilateral labyrinthectomy by action in the cerebellum and thalamus. PLoS one. 2015;10:e0120891.","journal-title":"PLoS one"},{"key":"7399_CR12","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ejphar.2015.11.041","volume":"769","author":"B Tighilet","year":"2015","unstructured":"Tighilet B, Leonard J, Bernard-Demanze L, Lacour M. Comparative analysis of pharmacological treatments with N-acetyl-DL-leucine (Tanganil) and its two isomers (N-acetyl-L-leucine and N-acetyl-D-leucine) on vestibular compensation: Behavioral investigation in the cat. Eur J Pharmacol. 2015;769:342\u20139.","journal-title":"Eur J Pharmacol"},{"key":"7399_CR13","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3390\/jcm9041050","volume":"9","author":"E Kaya","year":"2020","unstructured":"Kaya E, Smith DA, Smith C, Boland B, Strupp M, Platt FM. Beneficial effects of acetyl-DL-leucine (ADLL) in a mouse model of Sandhoff disease. J Clin Med. 2020;9:1050.","journal-title":"J Clin Med"},{"key":"7399_CR14","doi-asserted-by":"publisher","first-page":"e0229585","DOI":"10.1371\/journal.pone.0229585","volume":"15","author":"GC Churchill","year":"2020","unstructured":"Churchill GC, Strupp M, Galione A, Platt FM. Unexpected differences in the pharmacokinetics of N-acetyl-DL-leucine enantiomers after oral dosing and their clinical relevance. PLoS one. 2020;15:e0229585.","journal-title":"PLoS one"},{"key":"7399_CR15","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, G\u00f8tzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"key":"7399_CR16","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","volume":"66","author":"T Schmitz-H\u00fcbsch","year":"2006","unstructured":"Schmitz-H\u00fcbsch T, du Montcel ST, Baliko L, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66:1717\u201320.","journal-title":"Neurology"},{"key":"7399_CR17","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/pst.1638","volume":"13","author":"DV Mehrotra","year":"2014","unstructured":"Mehrotra DV. A recommended analysis for 2 \u00d7 2 crossover trials with baseline measurements. Pharm Stat. 2014;13:376\u201387.","journal-title":"Pharm Stat"},{"key":"7399_CR18","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1212\/01.wnl.0000324863.76290.19","volume":"71","author":"T Schmitz-H\u00fcbsch","year":"2008","unstructured":"Schmitz-H\u00fcbsch T, Giunti P, Stephenson DA, et al. SCA Functional Index: a useful compound performance measure for spinocerebellar ataxia. Neurology. 2008;71:486\u201392.","journal-title":"Neurology"},{"key":"7399_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2006.05.054","volume":"249","author":"C Iturriaga","year":"2006","unstructured":"Iturriaga C, Pineda M, Fern\u00e1ndez-Valero EM, Vanier MT, Coll MJ. Niemann-Pick C disease in Spain: clinical spectrum and development of a disability scale. J Neurol Sci. 2006;249:1\u20136.","journal-title":"J Neurol Sci"},{"key":"7399_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ymgme.2009.11.007","volume":"99","author":"M Pineda","year":"2010","unstructured":"Pineda M, Perez-Poyato MS, O\u2019Callaghan M, et al. Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: a case series. Mol Genet Metab. 2010;99:358\u201366.","journal-title":"Mol Genet Metab"},{"key":"7399_CR21","unstructured":"EuroQol Group. EQ-5D Instruments | About EQ-5D. 2017. 2017. Accessed at: https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-5l-about. Accessed 15 Feb 2020."},{"key":"7399_CR22","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1161\/STROKEAHA.108.515262","volume":"39","author":"TJ Quinn","year":"2008","unstructured":"Quinn TJ, Dawson J, Walters MR, Lees KR. Variability in modified Rankin scoring across a large cohort of international observers. Stroke. 2008;39:2975\u20139.","journal-title":"Stroke"},{"key":"7399_CR23","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/ajmg.a.38413","volume":"176","author":"L Kempf","year":"2018","unstructured":"Kempf L, Goldsmith JC, Temple R. Challenges of developing and conducting clinical trials in rare disorders. Am J Med Genet A. 2018;176:773\u201383.","journal-title":"Am J Med Genet A"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07399-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07399-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07399-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T02:03:53Z","timestamp":1685325833000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07399-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,29]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7399"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07399-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2048685\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,29]]},"assertion":[{"value":"29 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the responsible central research ethics committees\/institutional review boards, including the Ethics Committee of Ludwig Maximilian University of Munich (21\u20131269), National Institute of Child Diseases Bratislava Ethics Committee (EudraCT 2021\u2013005356-10), Ethics Committee of General University Hospital in Prague (56\/22 S-MEK), East Midlands \u2013 Derby Research Ethics Committee (1004498), Amsterdam UMC Locatie AMC Central Ethics Committee (NL79787.018.21), Mayo Clinic Institutional Review Board (22\u2013001734), Emory University Institutional Review Board (STUDY00003227) Switzerland Business Administration System for Ethics Committees (2022\u201300638), and Victoria Human Research Ethics Committee (HREC\/86167\/MH-2022).Informed consent will be obtained for all study participants by the principal investigator\/delegated investigator.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MF is a co-founder, shareholder, and chairman of IntraBio. TF and IB are officers and shareholders of IntraBio. CF Is an employee and shareholder of IntraBio. FP is a cofounder, shareholder, and consultant to IntraBio and consultant to Actelion. MS is a shareholder to IntraBio and consultant for Abbott, Actelion, AurisMedical, Heel, IntraBio, Sensorion, and Vertify; he has received speaker\u2019s honoraria from Abbott, Actelion, Auris Medical, Biogen, Eisai, Gr\u00fcnenthal, GSK, Henning Pharma, Interacoustics, Johnson & Johnson, MSD, Otometrics, Pierre-Fabre, TEVA, and UCB. AG and GC are cofounders, shareholder sand consultants to IntraBio. MP is a shareholder of IntraBio and has received consulting fees, honoraria, and research grants from Actelion Pharmaceuticals Ltd. and Biomarin. RK is a consultant to IntraBio. TBE received honoraria for lecturing from Actelion and Sanofi Genzyme and fees for the blinded rater services from IntraBio.IntraBio owns patents EP3359146, EP3416631, EP3482754, USPTO10905670, and USPTO11400067 (application 16\/324,301) related to treatment of lysosomal storage disorders and neurodegenerative diseases with acetyl-leucine and its analogs.IntraBio has pending patent applications EP19174007.5, EP20215877.0, PCT\/IB2017\/054928, PCT\/IB2017\/054929, PCT\/US2018\/056420, PCT\/IB2018\/054676, PCT\/US2018\/018420, PCT\/IB2019\/060525, PCT\/IB2019\/051214, PCT\/GB2017\/051090, PCT\/IB2020\/051767, PCT\/IB2020\/056096, and PCT\/IB2021\/050236 relating to treatment of lysosomal storage disorders, neurodegenerative diseases, and neurodegeneration with acetyl-leucine and its analogs.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"361"}}